Immunoadsorption in Autoimmune Long COVID
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About this trial
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.
This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.
This research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.
Eligibility criteria
Qualifiers
Long COVID based on the WHO-criteria
PEM according to the DSQ-PEM
BELL's functionality score 20-70%
Good health prior to the long COVID diagnosis (WHO performance score 0)
Disqualifiers
Medical history of clinically significant respiratory- or cardiovascular disease
Prior interventional cardiac procedure within 3 months prior to randomization
Active immunosuppresive treatment for systemic autoimmune disorders
Diabetes type 1
Trial design
Treatments tested in this trial
- Immunoadsorption
- Sham Comparator
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov